Proteomic approach to studying parkinson’s disease

[1]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[2]  Jeffrey H. Kordower,et al.  The role of α-synuclein in Parkinson's disease: insights from animal models , 2003, Nature Reviews Neuroscience.

[3]  V. Buchman,et al.  Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease , 2003, Neuropharmacology.

[4]  T. Flotte,et al.  A single-subunit NADH-quinone oxidoreductase renders resistance to mammalian nerve cells against complex I inhibition. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  A. Björklund,et al.  Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein: A new primate model of Parkinson's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Matthew P Frosch,et al.  The Formation of Highly Soluble Oligomers of α-Synuclein Is Regulated by Fatty Acids and Enhanced in Parkinson's Disease , 2003, Neuron.

[7]  C. Warren Olanow,et al.  Altered Proteasomal Function in Sporadic Parkinson's Disease , 2003, Experimental Neurology.

[8]  Todd B. Sherer,et al.  Subcutaneous Rotenone Exposure Causes Highly Selective Dopaminergic Degeneration and α-Synuclein Aggregation , 2003, Experimental Neurology.

[9]  T. Dawson,et al.  Rare genetic mutations shed light on the pathogenesis of Parkinson disease. , 2003, The Journal of clinical investigation.

[10]  K. Davies,et al.  Ubiquitin Conjugation Is Not Required for the Degradation of Oxidized Proteins by Proteasome* , 2003, The Journal of Biological Chemistry.

[11]  Smita Patel,et al.  Golgi Fragmentation Occurs in the Cells with Prefibrillar α-Synuclein Aggregates and Precedes the Formation of Fibrillar Inclusion* , 2002, The Journal of Biological Chemistry.

[12]  B. Bioulac,et al.  A ‘single toxin–double lesion’ rat model of striatonigral degeneration by intrastriatal 1-methyl-4-phenylpyridinium ion injection: a motor behavioural analysis , 2002, Neuroscience.

[13]  S. Totterdell,et al.  Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson’s disease , 2002, Brain Research.

[14]  Hideo Fujiwara,et al.  Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. , 2002, The Journal of clinical investigation.

[15]  P. Auluck,et al.  Pharmacological prevention of Parkinson disease in Drosophila , 2002, Nature Medicine.

[16]  M. Waterfield,et al.  Identification of novel candidates for replicative senescence by functional proteomics , 2002, Oncogene.

[17]  Robert Burke,et al.  Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Trojanowski,et al.  Parkinson's disease and related synucleinopathies are a new class of nervous system amyloidoses. , 2002, Neurotoxicology.

[19]  Makoto Hashimoto,et al.  Development of new treatments for Parkinson's disease in transgenic animal models: a role for beta-synuclein. , 2002, Neurotoxicology.

[20]  G. Cohen,et al.  Proteasome-mediated Degradation of Smac during Apoptosis: XIAP Promotes Smac Ubiquitination in Vitro * , 2002, The Journal of Biological Chemistry.

[21]  D. Butterfield,et al.  Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase‐related protein 2, α‐enolase and heat shock cognate 71 , 2002, Journal of neurochemistry.

[22]  P. Werner,et al.  Selective destruction of dopaminergic neurons by low concentrations of 6-OHDA and MPP+: protection by acetylsalicylic acid aspirin. , 2002, Parkinsonism & related disorders.

[23]  Todd B. Sherer,et al.  An In Vitro Model of Parkinson's Disease: Linking Mitochondrial Impairment to Altered α-Synuclein Metabolism and Oxidative Damage , 2002, The Journal of Neuroscience.

[24]  C. Olanow,et al.  Proteasome inhibition causes nigral degeneration with inclusion bodies in rats , 2002, Neuroreport.

[25]  M. Mann,et al.  Large-scale Proteomic Analysis of the Human Spliceosome References , 2006 .

[26]  L. Millen,et al.  Conformational Remodeling of Proteasomal Substrates by PA700, the 19 S Regulatory Complex of the 26 S Proteasome* , 2002, The Journal of Biological Chemistry.

[27]  P. Lansbury,et al.  Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. , 2002, Biochemistry.

[28]  Johannes Schwarz,et al.  Expression of mutant &agr;-synucleins enhances dopamine transporter-mediated MPP+ toxicity in vitro , 2002, Neuroreport.

[29]  C. Olanow,et al.  Selective loss of 20S proteasome α-subunits in the substantia nigra pars compacta in Parkinson's disease , 2002, Neuroscience Letters.

[30]  T. Montine,et al.  Mitochondrial DNA Deletions/Rearrangements in Parkinson Disease and Related Neurodegenerative Disorders , 2002, Journal of neuropathology and experimental neurology.

[31]  B. Cravatt,et al.  Proteomic profiling of mechanistically distinct enzyme classes using a common chemotype , 2002, Nature Biotechnology.

[32]  Nancy A. Jenkins,et al.  Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[33]  I. Ziv,et al.  Mutant and wild-type α-synuclein interact with mitochondrial cytochrome C oxidase , 2002, Journal of Molecular Neuroscience.

[34]  J. Trojanowski,et al.  The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases. , 2002, Free radical biology & medicine.

[35]  M. Barrachina,et al.  MPP+ increases α-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells , 2002, Brain Research.

[36]  B. Hyman,et al.  Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. , 2002, The American journal of pathology.

[37]  C. Dobson,et al.  Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases , 2002, Nature.

[38]  A. Björklund,et al.  Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of α-Synuclein in the Nigrostriatal System , 2002, The Journal of Neuroscience.

[39]  Rajesh Pahwa,et al.  Age at onset in two common neurodegenerative diseases is genetically controlled. , 2002, American journal of human genetics.

[40]  Mary F. Lopez,et al.  Applied proteomics: mitochondrial proteins and effect on function. , 2002, Circulation research.

[41]  Chung-Soo Lee,et al.  Protective effect of serotonin on 6-hydroxydopamine- and dopamine-induced oxidative damage of brain mitochondria and synaptosomes and PC12 cells , 2002, Neurochemistry International.

[42]  S. Shin,et al.  Formation and Removal of α-Synuclein Aggregates in Cells Exposed to Mitochondrial Inhibitors* , 2002, The Journal of Biological Chemistry.

[43]  Hanno Langen,et al.  The rat liver mitochondrial proteins , 2002, Electrophoresis.

[44]  D. Goodlett,et al.  Proteomics without polyacrylamide: qualitative and quantitative uses of tandem mass spectrometry in proteome analysis , 2002, Functional & Integrative Genomics.

[45]  R. Roth,et al.  Embryonic ventral mesencephalic grafts to the substantia nigra of MPTP‐treated monkeys: Feasibility relevant to multiple‐target grafting as a therapy for Parkinson's disease , 2002, The Journal of comparative neurology.

[46]  J. Growdon,et al.  Epidemiologic study of 203 sibling pairs with Parkinson’s disease , 2002, Neurology.

[47]  Shihua Li,et al.  Chaperone Suppression of Cellular Toxicity of Huntingtin Is Independent of Polyglutamine Aggregation* , 2001, The Journal of Biological Chemistry.

[48]  John Q. Trojanowski,et al.  Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease , 2001, Science.

[49]  E. Melamed,et al.  6-Hydroxydopamine Increases Ubiquitin-Conjugates and Protein Degradation: Implications for the Pathogenesis of Parkinson's Disease , 2001, Cellular and Molecular Neurobiology.

[50]  J. Smeitink,et al.  Mitochondrial oxidative phosphorylation system assembly in man: recent achievements , 2001, Current opinion in neurology.

[51]  D. Sulzer.  α-synuclein and cytosolic dopamine: Stabilizing a bad situation , 2001, Nature Medicine.

[52]  M. Spillantini,et al.  α‐Synuclein metabolism and aggregation is linked to ubiquitin‐independent degradation by the proteasome , 2001, FEBS letters.

[53]  David Blum,et al.  Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease , 2001, Progress in Neurobiology.

[54]  K. Davies,et al.  Protein oxidation and 20S proteasome-dependent proteolysis in mammalian cells , 2001, Cellular and Molecular Life Sciences CMLS.

[55]  J. Bergquist,et al.  Identification of nuclei associated proteins by 2D-gel electrophoresis and mass spectrometry , 2001, Journal of Neuroscience Methods.

[56]  B. Friguet,et al.  Oxidative Modification and Inactivation of the Proteasome during Coronary Occlusion/Reperfusion* , 2001, The Journal of Biological Chemistry.

[57]  Barry Halliwell,et al.  Failure of the ubiquitin–proteasome system in Parkinson's disease , 2001, Nature Reviews Neuroscience.

[58]  R. Aebersold,et al.  Differential stable isotope labeling of peptides for quantitation and de novo sequence derivation. , 2001, Rapid communications in mass spectrometry : RCM.

[59]  Nobutaka Hattori,et al.  Ubiquitination of a New Form of α-Synuclein by Parkin from Human Brain: Implications for Parkinson's Disease , 2001, Science.

[60]  P. Lansbury,et al.  Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. , 2001, Biochemistry.

[61]  David M. Smith,et al.  Ester Bond-containing Tea Polyphenols Potently Inhibit Proteasome Activity in Vitro and in Vivo * , 2001, The Journal of Biological Chemistry.

[62]  C. Ross,et al.  Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. , 2001, Human molecular genetics.

[63]  B. Chait,et al.  Enrichment analysis of phosphorylated proteins as a tool for probing the phosphoproteome , 2001, Nature Biotechnology.

[64]  K. Davies.  Degradation of oxidized proteins by the 20S proteasome. , 2001, Biochimie.

[65]  M. Vu,et al.  Proteasomes Modulate Balance Among Proapoptotic and Antiapoptotic Bcl-2 Family Members and Compromise Functioning of the Electron Transport Chain in Leukemic Cells1 , 2001, The Journal of Immunology.

[66]  R. Aebersold,et al.  Mass spectrometry in proteomics. , 2001, Chemical reviews.

[67]  K. McNaught,et al.  Proteasomal function is impaired in substantia nigra in Parkinson's disease , 2001, Neuroscience Letters.

[68]  F. Dabbeni-sala,et al.  Melatonin protects against 6‐OHDA‐induced neurotoxicity in rats: a role for mitochondrial complex I activity , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[69]  Virginia M. Y. Lee,et al.  Oxidative post‐translational modifications of α‐synuclein in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) mouse model of Parkinson's disease , 2001, Journal of neurochemistry.

[70]  J. Trojanowski,et al.  “Fatal Attractions” of Proteins: A Comprehensive Hypothetical Mechanism Underlying Alzheimer's Disease and Other Neurodegenerative Disorders , 2000, Annals of the New York Academy of Sciences.

[71]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[72]  P. Riederer,et al.  Crosslinking of α-synuclein by advanced glycation endproducts — an early pathophysiological step in Lewy body formation? , 2000, Journal of Chemical Neuroanatomy.

[73]  J. Trojanowski,et al.  Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.

[74]  Andrew P. VanDemark,et al.  Opening doors into the proteasome , 2000, Nature Structural Biology.

[75]  A. Goldberg,et al.  PAN, the proteasome-activating nucleotidase from archaebacteria, is a protein-unfolding molecular chaperone , 2000, Nature Cell Biology.

[76]  Mauro Fasano,et al.  Nuclear magnetic relaxation dispersion profiles of substantia nigra pars compacta in Parkinson’s disease patients are consistent with protein aggregation , 2000, Neurochemistry International.

[77]  S. Gygi,et al.  Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[78]  J. Trojanowski,et al.  Neurodegeneration with Brain Iron Accumulation, Type 1 Is Characterized by α-, β-, and γ-Synuclein Neuropathology , 2000 .

[79]  A. Davies,et al.  Induction of neuronal death by α‐synuclein , 2000, The European journal of neuroscience.

[80]  E. Masliah,et al.  α-Synuclein Promotes Mitochondrial Deficit and Oxidative Stress , 2000 .

[81]  R. Jansen.  Origin and persistence of the mitochondrial genome. , 2000, Human reproduction.

[82]  P. Lansbury,et al.  Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson’s disease? , 2000, Nature Cell Biology.

[83]  B. Giasson,et al.  Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. , 2000, The Journal of biological chemistry.

[84]  G. Kroemer,et al.  Simplification of complex peptide mixtures for proteomic analysis: Reversible biotinylation of cysteinyl peptides , 2000, Electrophoresis.

[85]  P. Gluckman,et al.  N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats , 2000, Brain Research.

[86]  W. Bender,et al.  A Drosophila model of Parkinson's disease , 2000, Nature.

[87]  M. Mostert,et al.  Structural and functional characterization of 20S and 26S proteasomes from bovine brain. , 2000, Brain research. Molecular brain research.

[88]  T. Montine,et al.  Enhancement of Dopaminergic Neurotoxicity by the Mercapturate of Dopamine , 2000, Journal of neurochemistry.

[89]  B. Chait,et al.  The Yeast Nuclear Pore Complex: Composition, Architecture, and Transport Mechanism , 2000 .

[90]  L. Mucke,et al.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. , 2000, Science.

[91]  K. Marder,et al.  Mitochondrial DNA mutations in complex I and tRNA genes in Parkinson’s disease , 2000, Neurology.

[92]  G. Kroemer,et al.  Mass spectrometric identification of proteins released from mitochondria undergoing permeability transition , 2000, Cell Death and Differentiation.

[93]  M. Vila,et al.  α‐Synuclein Up‐Regulation in Substantia Nigra Dopaminergic Neurons Following Administration of the Parkinsonian Toxin MPTP , 2000, Journal of neurochemistry.

[94]  R. Mandel.  Effect of Acute l -Dopa Pretreatment on Apomorphine-Induced Rotational Behavior in a Rat Model of Parkinson's Disease , 2000, Experimental Neurology.

[95]  Heidi Phillips,et al.  Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System , 2000, Neuron.

[96]  Philippe Hantraye,et al.  MPTP induces alpha‐synuclein aggregation in the substantia nigra of baboons , 2000, Neuroreport.

[97]  R. Roth,et al.  Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment , 1999, Neuroscience.

[98]  S. Gygi,et al.  Quantitative analysis of complex protein mixtures using isotope-coded affinity tags , 1999, Nature Biotechnology.

[99]  C. Slaughter,et al.  The Proteasome, a Novel Protease Regulated by Multiple Mechanisms* , 1999, The Journal of Biological Chemistry.

[100]  J. Yates,et al.  Direct analysis of protein complexes using mass spectrometry , 1999, Nature Biotechnology.

[101]  T. Montine,et al.  Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. , 1999, The American journal of pathology.

[102]  A. Fink.  Chaperone-mediated protein folding. , 1999, Physiological reviews.

[103]  Erwan Bezard,et al.  Absence of MPTP-Induced Neuronal Death in Mice Lacking the Dopamine Transporter , 1999, Experimental Neurology.

[104]  R. Kopito,et al.  Aggresomes: A Cellular Response to Misfolded Proteins , 1998, The Journal of cell biology.

[105]  M. Bolotin-Fukuhara,et al.  A mutation in a novel yeast proteasomal gene, RPN11/MPR1, produces a cell cycle arrest, overreplication of nuclear and mitochondrial DNA, and an altered mitochondrial morphology. , 1998, Molecular biology of the cell.

[106]  Georg Auburger,et al.  The ubiquitin pathway in Parkinson's disease , 1998, Nature.

[107]  M. Polymeropoulos.  Autosomal dominant Parkinson’s disease , 1998, Journal of Neurology.

[108]  J Q Trojanowski,et al.  Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α‐synuclein , 1998, Annals of neurology.

[109]  J. Langston,et al.  Epidemiology versus genetics in parkinson's disease: Progress in resolving an age‐old debate , 1998, Annals of neurology.

[110]  P. Jenner,et al.  Understanding cell death in parkinson's disease , 1998, Annals of neurology.

[111]  Langston Jw.  Epidemiology versus genetics in parkinson's disease: Progress in resolving an age-old debate , 1998 .

[112]  K. Tipton,et al.  Mechanism of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine and its prevention by desferrioxamine. , 1998, European Journal of Pharmacology.

[113]  W. Welch,et al.  Neurodegeneration: Chaperoning brain diseases , 1998, Nature.

[114]  T. Montine,et al.  Neurotoxicity of Endogenous Cysteinylcatechols , 1997, Experimental Neurology.

[115]  G. Dryhurst,et al.  Irreversible Inhibition of Mitochondrial Complex I by 7‐(2‐Aminoethyl)‐3,4‐Dihydro‐5‐Hydroxy‐2H‐1,4‐Benzothiazine‐3‐Carboxylic Acid (DHBT‐1): A Putative Nigral Endotoxin of Relevance to Parkinson's Disease , 1997, Journal of neurochemistry.

[116]  D. D. Di Monte,et al.  Inhibition of Monoamine Oxidase Contributes to the Protective Effect of 7‐Nitroindazole Against MPTP Neurotoxicity , 1997, Journal of neurochemistry.

[117]  A. Lees,et al.  A Generalised Increase in Protein Carbonyls in the Brain in Parkinson's but Not Incidental Lewy Body Disease , 1997, Journal of neurochemistry.

[118]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[119]  M. Boyd,et al.  Evidence for generation of oxidative stress in brain by MPTP: in vitro and in vivo studies in mice , 1997, Brain Research.

[120]  K. Hoyt,et al.  Mechanisms of Dopamine-Induced Cell Death in Cultured Rat Forebrain Neurons: Interactions with and Differences from Glutamate-Induced Cell Death , 1997, Experimental Neurology.

[121]  K. Kosaka,et al.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) , 1996, Neurology.

[122]  R. Swerdlow,et al.  Origin and functional consequences of the complex I defect in Parkinson's disease , 1996, Annals of neurology.

[123]  Xiaodong Wang,et al.  Induction of Apoptotic Program in Cell-Free Extracts: Requirement for dATP and Cytochrome c , 1996, Cell.

[124]  N. Hattori,et al.  Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[125]  J. Cano,et al.  Effect of intraventricular injection of 1-methyl-4-phenylpyridinium: protection by acetyl-L-carnitine , 1995, Human & experimental toxicology.

[126]  M. Beal,et al.  Aging, energy, and oxidative stress in neurodegenerative diseases , 1995, Annals of neurology.

[127]  Robert Hill,et al.  Low platelet mitochondrial complex I and complex II/III activity in early untreated parkinson's disease , 1995, Annals of neurology.

[128]  C. L. Li,et al.  Lipid peroxidation in brain: interactions of L-DOPA/dopamine with ascorbate and iron. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[129]  E. Montgomery.  Heavy metals and the etiology of Parkinson's disease and other movement disorders. , 1995, Toxicology.

[130]  R. Bartrons,et al.  Cerebrospinal dopamine metabolites in rats after intrastriatal administration of 6-hydroxydopamine or 1-methyl-4-phenylpyridinium ion , 1995, Brain Research.

[131]  D. Murphy,et al.  In Vivo Generation of Hydroxyl Radicals and MPTP‐Induced Dopaminergic Toxicity in the Basal Ganglia , 1994, Annals of the New York Academy of Sciences.

[132]  K. H. White,et al.  Mitochondrial morphological and functional defects in yeast caused by yme1 are suppressed by mutation of a 26S protease subunit homologue. , 1994, Molecular biology of the cell.

[133]  V. Bergdall,et al.  Effects of Nerve Growth Factor Infusion on Behavioral Recovery and Graft Survival Following Intraventricular Adrenal Medulla Grafts in the Unilateral 6-Hydroxydopamine Lesioned Rat , 1994, Journal of neural transplantation & plasticity.

[134]  A. Zuddas,et al.  In Brown Norway Rats, MPP+ Is Accumulated in the Nigrostriatal Dopaminergic Terminals but It Is Not Neurotoxic: A Model of Natural Resistance to MPTP Toxicity , 1994, Experimental Neurology.

[135]  R. Benecke,et al.  Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. , 1993, Brain : a journal of neurology.

[136]  T. Haystead,et al.  Gamma-phosphate-linked ATP-sepharose for the affinity purification of protein kinases. Rapid purification to homogeneity of skeletal muscle mitogen-activated protein kinase kinase. , 1993, European journal of biochemistry.

[137]  C. Piantadosi,et al.  Mitochondrial oxidative stress after carbon monoxide hypoxia in the rat brain. , 1992, The Journal of clinical investigation.

[138]  B. Chait,et al.  Weighing naked proteins: practical, high-accuracy mass measurement of peptides and proteins. , 1992, Science.

[139]  D. Wallace.  Mitochondrial genetics: a paradigm for aging and degenerative diseases? , 1992, Science.

[140]  E. Abercrombie,et al.  Neurochemical Responses to 6‐Hydroxydopamine and L‐Dopa Therapy: Implications for Parkinson's Disease a , 1992, Annals of the New York Academy of Sciences.

[141]  M. Beal,et al.  Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? , 1992, Annals of neurology.

[142]  K. Takeshige,et al.  1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. , 1990, Biochemical and biophysical research communications.

[143]  S. Ohta,et al.  Postmortem changes in mitochondrial respiratory enzymes in brain and a preliminary observation in Parkinson's disease , 1990, Journal of the Neurological Sciences.

[144]  C. Marsden,et al.  Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.

[145]  C. Altar,et al.  1-Methyl-4-phenylpyridine (MPP+): regional dopamine neuron uptake, toxicity, and novel rotational behavior following dopamine receptor proliferation. , 1986, European journal of pharmacology.

[146]  R. Duvoisin,et al.  Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: Implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity , 1985, Neuroscience Letters.

[147]  C. Rebert,et al.  Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey , 1984, Brain Research.

[148]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[149]  J. LaManna,et al.  Abnormalities of cerebral oxidative metabolism in animal models of Parkinson disease , 1982, Neurology.

[150]  B. Sahakian,et al.  Circling behavior in rats with partial, unilateral nigro-striatal lesions: Effect of amphetamine, apomorphine, and DOPA , 1980, Pharmacology Biochemistry and Behavior.

[151]  D. Graham.  Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. , 1978, Molecular pharmacology.

[152]  D. Graham,et al.  Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. , 1978, Molecular pharmacology.

[153]  B Chance,et al.  The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen. , 1973, The Biochemical journal.

[154]  G. Cohen,et al.  In vivo generation of hydrogen peroxide from 6-hydroxydopamine , 1972, Experientia.

[155]  U. Ungerstedt,et al.  Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. , 1971, Acta physiologica Scandinavica. Supplementum.

[156]  H. Thoenen,et al.  Model experiments on the molecular mechanism of action of 6-hydroxydopamine. , 1971, Molecular pharmacology.

[157]  C. Chiueh,et al.  In vivo trapping of hydroxyl free radicals in the striatum utilizing intracranial microdialysis perfusion of salicylate: effects of MPTP, MPDP+, and MPP+ , 2005, Journal of Neural Transmission / General Section JNT.

[158]  P. Riederer,et al.  Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man , 2005, Journal of Neural Transmission.

[159]  Jeffrey H Kordower,et al.  The role of alpha-synuclein in Parkinson's disease: insights from animal models. , 2003, Nature reviews. Neuroscience.

[160]  V. Buchman,et al.  Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease. , 2003, Neuropharmacology.

[161]  A. Schapira,et al.  Genetic and environmental factors in the cause of Parkinson's disease , 2003, Annals of neurology.

[162]  J. Trojanowski,et al.  Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. , 2002, Science.

[163]  M. Barrachina,et al.  MPP+ increases alpha-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells. , 2002, Brain research.

[164]  I. Ziv,et al.  Mutant and wild-type alpha-synuclein interact with mitochondrial cytochrome C oxidase. , 2002, Journal of molecular neuroscience : MN.

[165]  J. Trojanowski,et al.  Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. , 2002, The Journal of clinical investigation.

[166]  T. Montine,et al.  The mitochondrial common deletion in Parkinson's disease and related movement disorders. , 2002, Parkinsonism & related disorders.

[167]  K. Jellinger,et al.  Recent developments in the pathology of Parkinson's disease. , 2002, Journal of neural transmission. Supplementum.

[168]  D. Price,et al.  Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[169]  W. Dröge.  Free radicals in the physiological control of cell function. , 2002, Physiological reviews.

[170]  D. Sulzer,et al.  Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. , 2000, Neuron.

[171]  J. Brosens,et al.  Redefining endometriosis: is deep endometriosis a progressive disease? , 2000, Human reproduction.

[172]  M. Beal,et al.  A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease , 1999, BioFactors.

[173]  W. Baumeister,et al.  The 26S proteasome: a molecular machine designed for controlled proteolysis. , 1999, Annual review of biochemistry.

[174]  R. Krüger,et al.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.

[175]  S E Ide,et al.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.

[176]  K. Jellinger,et al.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. , 1996, Neurology.

[177]  J. Langston,et al.  Similarities and differences between MPTP-induced parkinsonsim and Parkinson's disease. Neuropathologic considerations. , 1993, Advances in neurology.

[178]  M. Okada,et al.  Central depletion of dopamine in rats by 1-methyl-4-phenylpyridine. , 1989, Life sciences.

[179]  G. Cohen.  Monoamine oxidase, hydrogen peroxide, and Parkinson's disease. , 1987, Advances in neurology.

[180]  G. Cohen.  The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence. , 1983, Journal of neural transmission. Supplementum.

[181]  B. Steinmann,et al.  Mass fragmentography of dopamine and 6-hydroxydopamine. Application to the determination of dopamine in human brain biopsies from the caudate nucleus. , 1974, Journal of chromatography.

[182]  Yeast Yeast 2000; 17: 81±87. Review Article , 2022 .